Counterpoint Mutual Funds LLC Purchases Shares of 21,374 OraSure Technologies, Inc. (NASDAQ:OSUR)

Counterpoint Mutual Funds LLC purchased a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 21,374 shares of the medical instruments supplier’s stock, valued at approximately $131,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OSUR. AJOVista LLC purchased a new stake in shares of OraSure Technologies during the 4th quarter worth about $39,000. Dynamic Technology Lab Private Ltd purchased a new position in OraSure Technologies in the 4th quarter worth approximately $113,000. Baader Bank Aktiengesellschaft purchased a new position in OraSure Technologies in the 4th quarter worth approximately $115,000. Diversified Trust Co boosted its holdings in OraSure Technologies by 17.7% in the 4th quarter. Diversified Trust Co now owns 16,031 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 2,406 shares during the period. Finally, Raymond James & Associates purchased a new position in OraSure Technologies in the 4th quarter worth approximately $133,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Wall Street Analysts Forecast Growth

OSUR has been the topic of a number of recent analyst reports. StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. cut their target price on OraSure Technologies from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Monday, May 13th. Finally, Evercore ISI cut their target price on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research report on Thursday, April 4th. Three research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.63.

OraSure Technologies Price Performance

Shares of OSUR stock traded down $0.02 on Wednesday, hitting $4.20. 1,391,871 shares of the stock traded hands, compared to its average volume of 1,065,742. The company has a market capitalization of $310.63 million, a PE ratio of 14.00 and a beta of 0.14. OraSure Technologies, Inc. has a 1-year low of $4.11 and a 1-year high of $8.45. The company’s fifty day moving average is $4.92 and its 200 day moving average is $6.37.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.04. The business had revenue of $54.10 million for the quarter, compared to analyst estimates of $52.27 million. OraSure Technologies had a return on equity of 7.68% and a net margin of 7.50%. The business’s revenue was down 65.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.37 EPS. As a group, equities research analysts expect that OraSure Technologies, Inc. will post -0.08 EPS for the current year.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.